BioMarin and n-Lorem partner on early research for ReNU syndrome therapy

Summary

BioMarin Pharmaceutical and n-Lorem have entered into a partnership to conduct early-stage research on a ReNU syndrome therapy. The collaboration represents an early research stage initiative between the two companies.